SCHEMBL20705295

SCHEMBL20705295

CC(O)C(=O)c1cc(F)c(F)c(F)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 7/20 0.62
CES1 P23141 7/20 0.62
SLC6A3 Q01959 2/20 0.39
CHRNA1 P02708 1/20 0.39
CHRNG P07510 1/20 0.39
CHRNB1 P11230 1/20 0.39
CHRNB2 P17787 1/20 0.39
SLC6A2 P23975 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39
CHRND Q07001 1/20 0.39
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA4 P22748 2/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
MAOB P27338 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
ANPEP P15144 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21503691 0.84 CES2 (0.59) CES2CES1SLC6A3CHRNA1CHRNG
SCHEMBL20702960 0.81 CES2 (0.55) CES2CES1SLC6A3CHRNA1CHRNG
SCHEMBL6955765 0.79 CES2 (0.62) CES2CES1SLC6A3CHRNA1CHRNG
SCHEMBL9078831 0.76 CES2 (0.59) CES2CES1SLC6A3CHRNA1CHRNG
SCHEMBL10782883 0.72 CES2 (0.55) CES2CES1SLC6A3CHRNA1CHRNG
SCHEMBL823677 0.72 CES2 (0.64) CES2CES1CA1CA2CA4
SCHEMBL20702882 0.71 HPGD (0.45) SMN1; SMN2LMNAMAPK1HTTRAB9A
SCHEMBL20702884 0.71 HPGD (0.45) SMN1; SMN2LMNAMAPK1HTTRAB9A
SCHEMBL29077329 0.71 CES2 (0.52) CES2CES1SLC6A3SLC6A2CA1
SCHEMBL4869727 0.71 CES2 (0.52) CES2CES1SLC6A3SLC6A2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258323-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2025-03-25 US disclosed
US-11773070-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2023-10-03 US disclosed
US-11773070-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2023-10-03 US disclosed
US-11773070-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2023-10-03 US disclosed
EP-3661517-B1 DIHYDROOXADIAZINONES BAYER AG (DE) 2023-09-13 EP disclosed
EP-3661517-B1 DIHYDROOXADIAZINONES BAYER AG (DE) 2023-09-13 EP disclosed
US-20230017200-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2023-01-19 US disclosed
US-20230017200-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2023-01-19 US disclosed
US-20220396554-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2022-12-15 US disclosed
US-20220396554-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2022-12-15 US disclosed
US-11427553-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2022-08-30 US disclosed
US-20200369633-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2020-11-26 US disclosed
US-20200369633-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2020-11-26 US disclosed
EP-3661517-A1 DIHYDROOXADIAZINONES Bayer Aktiengesellschaft (DE) 2020-06-10 EP disclosed
WO-2019025562-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2019-02-07 WO disclosed
WO-2019025562-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2019-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369633-A1 DIHYDROOXADIAZINONES CCND2, CCNT2, CCND1 CES2 4389/4885CES1 2438/4885SLC6A3 4746/4885
US-11773070-B2 Dihydrooxadiazinones CCND2, DPYD, DHPS CES2 4179/4885CES1 2194/4885SLC6A3 4685/4885
US-20220396554-A1 DIHYDROOXADIAZINONES CCND2, DPYD, DHPS CES2 4179/4885CES1 2194/4885SLC6A3 4685/4885
US-12258323-B2 Dihydrooxadiazinones CCND2, CCNT2, CCND1 CES2 4389/4885CES1 2438/4885SLC6A3 4746/4885
US-20230017200-A1 DIHYDROOXADIAZINONES CCND2, CCNT2, CCND1 CES2 4389/4885CES1 2438/4885SLC6A3 4746/4885
US-11427553-B2 Dihydrooxadiazinones CCND2, CCNT2, CCND1 CES2 4389/4885CES1 2438/4885SLC6A3 4746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.